Rex B. Mowat

1.6k total citations
38 papers, 887 citations indexed

About

Rex B. Mowat is a scholar working on Oncology, Pathology and Forensic Medicine and Cancer Research. According to data from OpenAlex, Rex B. Mowat has authored 38 papers receiving a total of 887 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 8 papers in Pathology and Forensic Medicine and 8 papers in Cancer Research. Recurrent topics in Rex B. Mowat's work include Colorectal Cancer Treatments and Studies (7 papers), Genetic factors in colorectal cancer (6 papers) and Nutritional Studies and Diet (4 papers). Rex B. Mowat is often cited by papers focused on Colorectal Cancer Treatments and Studies (7 papers), Genetic factors in colorectal cancer (6 papers) and Nutritional Studies and Diet (4 papers). Rex B. Mowat collaborates with scholars based in United States, Canada and South Korea. Rex B. Mowat's co-authors include Leonard B. Saltz, Donna Niedzwiecki, Jeffrey A. Meyerhardt, Robert J. Mayer, Renaud Whittom, Alexander Hantel, Al B. Benson, Alan P. Venook, Charles S. Fuchs and Shuji Ogino and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.

In The Last Decade

Rex B. Mowat

38 papers receiving 864 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rex B. Mowat United States	14	511	232	161	150	143	38	887
Page E. Abrahamson United States	16	576 1.1×	176 0.8×	176 1.1×	151 1.0×	124 0.9×	25	1.0k
Jinhee Hur United States	15	313 0.6×	149 0.6×	90 0.6×	173 1.2×	220 1.5×	24	727
Petra Seibold Germany	18	405 0.8×	97 0.4×	202 1.3×	115 0.8×	72 0.5×	41	831
Nikhil K. Khankari United States	14	337 0.7×	114 0.5×	163 1.0×	80 0.5×	107 0.7×	37	797
Ting‐Yuan David Cheng United States	16	236 0.5×	144 0.6×	132 0.8×	88 0.6×	121 0.8×	61	788
Syed Hasan Raza Jafri United States	11	349 0.7×	184 0.8×	88 0.5×	96 0.6×	47 0.3×	29	860
Haa‐Na Song South Korea	16	361 0.7×	201 0.9×	83 0.5×	89 0.6×	41 0.3×	47	815
Alfredo Tartarone Italy	17	432 0.8×	116 0.5×	132 0.8×	68 0.5×	61 0.4×	61	1.1k
Shelley M. Enger United States	20	786 1.5×	109 0.5×	413 2.6×	142 0.9×	167 1.2×	26	1.2k
Yuko Yamamura United States	17	345 0.7×	113 0.5×	219 1.4×	176 1.2×	109 0.8×	31	1.1k

Countries citing papers authored by Rex B. Mowat

Since Specialization

Citations

This map shows the geographic impact of Rex B. Mowat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rex B. Mowat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rex B. Mowat more than expected).

Fields of papers citing papers by Rex B. Mowat

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rex B. Mowat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rex B. Mowat. The network helps show where Rex B. Mowat may publish in the future.

Co-authorship network of co-authors of Rex B. Mowat

This figure shows the co-authorship network connecting the top 25 collaborators of Rex B. Mowat. A scholar is included among the top collaborators of Rex B. Mowat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rex B. Mowat. Rex B. Mowat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lee, Hun Ju, Jeremy S. Abramson, Nancy L. Bartlett, et al.. (2022). Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early Stage Classic Hodgkin Lymphoma: Interim Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part C). Blood. 140(Supplement 1). 9399–9401. 3 indexed citations

Choucair, Khalil, Abdurahman Alloghbi, Laura Stanbery, et al.. (2020). PIK3CA gene aberrancy and role in targeted therapy of solid malignancies. Cancer Gene Therapy. 27(9). 634–644. 29 indexed citations

Blarigan, Erin L. Van, Charles S. Fuchs, Donna Niedzwiecki, et al.. (2018). Marine ω-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). Cancer Epidemiology Biomarkers & Prevention. 27(4). 438–445. 50 indexed citations

Fuchs, Charles S., Donna Niedzwiecki, Xing Ye, et al.. (2017). Long-chain omega-3 fatty acid and fish intake after colon cancer diagnosis and disease-free, recurrence-free, and overall survival in CALGB 89803 (Alliance).. Journal of Clinical Oncology. 35(4_suppl). 585–585. 4 indexed citations

Lawrence, Yaacov Richard, Jennifer Moughan, Anthony M. Magliocco, et al.. (2017). Expression of the DNA repair gene MLH1 correlates with survival in patients who have resected pancreatic cancer and have received adjuvant chemoradiation: NRG Oncology RTOG Study 9704. Cancer. 124(3). 491–498. 8 indexed citations

Miller, Robert C., Daniel G. Petereit, Jeff A. Sloan, et al.. (2016). N08C9 (Alliance): A Phase 3 Randomized Study of Sulfasalazine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy. International Journal of Radiation Oncology*Biology*Physics. 95(4). 1168–1174. 16 indexed citations

Sio, Terence T., Philip J. Atherton, Brandon Birckhead, et al.. (2016). Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Supportive Care in Cancer. 24(9). 3847–3855. 7 indexed citations

Yoon, Han‐Seung, Nathan R. Foster, Preston D. Steen, et al.. (2015). Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance). Annals of Oncology. 27(2). 339–344. 37 indexed citations

Miller, Robert C., Daniel G. Petereit, Jeff A. Sloan, et al.. (2014). Primary and Secondary Endpoint Analysis of N08C9 (Alliance): A Phase 3 Randomized Trial of Sulfasalazine Versus Placebo in the Prevention of Acute Radiation Enteritis. International Journal of Radiation Oncology*Biology*Physics. 90(1). S86–S86. 1 indexed citations

10.

Fuchs, Michael, Kaori Sato, Donna Niedzwiecki, et al.. (2014). Sugar-Sweetened Beverage Intake and Cancer Recurrence and Survival in CALGB 89803 (Alliance). PLoS ONE. 9(6). e99816–e99816. 57 indexed citations

11.

Alberts, Steven R., Tiffany M. Yu, Robert J. Behrens, et al.. (2014). Comparative Economics of a 12-Gene Assay for Predicting Risk of Recurrence in Stage II Colon Cancer. PharmacoEconomics. 32(12). 1231–1243. 13 indexed citations

12.

Pisansky, Thomas M., Stephanie L. Pugh, Richard E. Greenberg, et al.. (2014). Tadalafil for Prevention of Erectile Dysfunction After Radiotherapy for Prostate Cancer. JAMA. 311(13). 1300–1300. 46 indexed citations

13.

Ogino, Shuji, Yu Imamura, Mai Yamauchi, et al.. (2013). Predictive and Prognostic Analysis of PIK3CA Mutation in Stage III Colon Cancer Intergroup Trial. JNCI Journal of the National Cancer Institute. 105(23). 1789–1798. 36 indexed citations

14.

Jeon, Justin Y., Kaori Sato, Donna Niedzwiecki, et al.. (2013). Impact of Physical Activity After Cancer Diagnosis on Survival in Patients With Recurrent Colon Cancer: Findings From CALGB 89803/Alliance. Clinical Colorectal Cancer. 12(4). 233–238. 30 indexed citations

15.

Jatoi, Aminah, Jorge J. Nieva, Rui Qin, et al.. (2012). A Pilot Study of Long-Acting Octreotide for Symptomatic Malignant Ascites. Oncology. 82(6). 315–320. 14 indexed citations

16.

Meyerhardt, Jeffrey A., Kaori Sato, Donna Niedzwiecki, et al.. (2012). Dietary Glycemic Load and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings From CALGB 89803. JNCI Journal of the National Cancer Institute. 104(22). 1702–1711. 118 indexed citations

17.

Tempero, Margaret A., K.A De Winter, Sanjay Kakar, et al.. (2011). S100A2 as a prognostic marker in patients receiving adjuvant therapy for pancreatic cancer (PC): A secondary analysis of RTOG 9704.. Journal of Clinical Oncology. 29(15_suppl). 4118–4118. 3 indexed citations

18.

Foster, Nathan R., Muhammad Salim, Patrick J. Flynn, et al.. (2011). Randomized phase II trial of panitumumab (P), erlotinib (E), and gemcitabine (G) versus erlotinib-gemcitabine in patients with untreated, metastatic pancreatic adenocarcinoma.. Journal of Clinical Oncology. 29(4_suppl). 238–238. 10 indexed citations

19.

Mowat, Rex B., et al.. (2004). Chemotherapy ordering process: Safety and efficiency considerations. Journal of Clinical Oncology. 22(14_suppl). 6110–6110. 1 indexed citations

20.

Loprinzi, Charles L., John W. Kugler, Jeff A. Sloan, et al.. (1999). Lack of Effect of Coumarin in Women with Lymphedema after Treatment for Breast Cancer. New England Journal of Medicine. 340(5). 346–350. 121 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact